Monitor for Nasdaq's decision on the initial listing application before July 20. Approval would clear the way for the preferred stock conversion vote, potentially increasing share count. Denial could threaten Nasdaq listing status and trigger a sharp sell-off. The stock's $7M market cap amplifies binary risk around this event.
Price Chart
Executive Summary
TransCode Therapeutics adjourned its 2026 Annual Meeting to July 20, 2026, pending Nasdaq's review of its initial listing application related to the conversion of Series A and Series B Non-Voting Convertible Preferred Stock into common stock. All proposals have received preliminary stockholder support, but the vote on the conversion cannot proceed without Nasdaq approval. The outcome of Nasdaq's review is uncertain, creating a near-term catalyst for the stock.
Key Facts
- Annual Meeting adjourned from July 2 to July 20, 2026 at 9:30 a.m. ET
- Nasdaq has not completed review of initial listing application under Rule 5110(a)
- Proposal 1 involves conversion of Series A and Series B Non-Voting Convertible Preferred Stock into common stock
- All proposals have received necessary support based on preliminary voting reports
- Company believes it currently satisfies initial listing criteria but no assurances given
Financial Impact
No financial figures disclosed; potential dilution from preferred stock conversion is contingent on Nasdaq approval
Risk Factors
- Nasdaq may deny initial listing application, preventing the conversion vote and potentially leading to delisting
- Conversion of preferred stock would dilute common shareholders, though terms are undisclosed
- Adjournment signals regulatory uncertainty; extended delay could erode investor confidence
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-080311 |
| Document: 0001104659-26-080311-index-headers.html | 0001104659-26-080311 |
| Document: 0001104659-26-080311-index.html | 0001104659-26-080311 |
| Document: 0001104659-26-080311.txt | 0001104659-26-080311 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | 8-K | $1.71 $1.71 | ▼ −0.26% | ▼ −0.23% | $1.71 (−0.23%) |
Sep 21, 2026 5w ago | 3 | $1.77 $1.68 | ▼ −5.08% | ▼ −4.52% | $1.71 (−3.62%) |
Sep 11, 2026 6w ago | 8-K | $1.65 $1.63 | ▲ +1.21% | ▲ +3.48% | $1.71 (−3.39%) |
Jul 2, 2026 16w ago | 8-K | $8.61 $4.22 | ▼ −50.99% | ▼ −51.84% | $1.71 (−80.19%) |
Jun 18, 2026 18w ago | 8-K | $4.70 $8.27 | ▲ +75.96% | ▲ +75.42% | $1.71 (−63.70%) |
Jun 3, 2026 20w ago | 8-K | $5.04 $8.61 | ▲ +70.83% | ▲ +71.83% | $1.71 (−66.15%) |
May 26, 2026 21w ago | DEFA14A | $5.39 $4.94 | ▲ +8.35% | ▲ +6.40% | $1.71 (+68.35%) |
Apr 30, 2026 25w ago | S-3 | $7.83 $5.44 | ▲ +30.59% | ▲ +35.85% | $1.71 (+78.21%) |
Apr 7, 2026 28w ago | 8-K | $8.70 $7.74 | ▲ +11.03% | ▲ +20.82% | $1.71 (+80.39%) |
Mar 3, 2026 33w ago | DEFA14A | $9.84 $8.69 | ▼ −11.69% | ▼ −7.27% | $1.71 (−82.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers